<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054479</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-238</org_study_id>
    <nct_id>NCT04054479</nct_id>
  </id_info>
  <brief_title>Penehyclidine for PONV Prophylaxis After Strabismus Surgery</brief_title>
  <official_title>The Effect of Penehyclidine on Postoperative Nausea and Vomiting After Strabismus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled for elective strabismus surgery under general anesthesia in the First
      Affiliated Hospital of Nanjing Medical University will be included in this study.

      Patients 1)ASA I or II, 2)aged 3-65 years, 3)scheduled for elective strabismus surgery under
      general anesthesia, will be included in the study. Patients 1)had prior PONV, 2)severe motion
      sickness, 3)a history of ophthalmic surgery, 4)had received drugs known to have antiemetic
      effects, will be excluded from the study.

      The primary aim is to evaluate the prophylaxis effect of penehyclidine(a novel long acting
      selective anticholinergic agent developed in China) on postoperative nausea and vomiting
      after strabismus surgery. Secondary outcomes include the effect of PONV risk factors and
      surgical technique on PONV rank score, occurance of oculocardiac reflex, time to extubation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PONV</measure>
    <time_frame>From extubation to 48 hours after surgery</time_frame>
    <description>Occurance of postoperative nausea and vomiting after strabismus surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>PONV</condition>
  <arm_group>
    <arm_group_label>Penehyclidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive penehyclidine after anesthesia intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive normal saline after anesthesia intubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penehyclidine</intervention_name>
    <description>Patients receive penehyclidine 10Î¼g/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.</description>
    <arm_group_label>Penehyclidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I or II

          -  Aged 3-65 years

          -  Scheduled for elective strabismus surgery under general anesthesia

        Exclusion Criteria:

          -  Had prior PONV

          -  Severe motion sickness

          -  A history of ophthalmic surgery

          -  Had received drugs known to have antiemetic effects in 24h before surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhengnian Ding, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaofei Cao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Lu, M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiacheng Sun, M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Penehyclidine</keyword>
  <keyword>PONV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

